Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, organised by EuropaBio and conference partners.
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
Lengnau will become the newest site in Thermo Fisher Scientific’s biologics manufacturing network. The site is to be completed in 2022 and its staff of 200 will join the company.
BionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.
Post-Brexit, UK ditches the strict EU regulation for genetic engineering: in future, gene-edited crops will be assessed just like any other new variety, the government said.
A comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
AstraZeneca has teamed up with RNA vaccine and therapeutic developer VaxEquity, investing US$195m in milestone payments alone.
The EIF has invested €25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
Boehringer Ingelheim has acquired Texan biotech Abexxa Biologics Inc., further expanding its cancer immunotherapy pipeline.
AstraZeneca